keyword
https://read.qxmd.com/read/38646076/the-first-case-report-of-de-novo-crohn-s-disease-after-heart-transplantation-successfully-treated-with-ustekinumab
#1
Shun Okamura, Chie Bujo, Eisuke Amiya, Ken Kurokawa, Masaru Hatano, Junichi Ishida, Masaki Tsuji, Sozaburo Ihara, Keita Murakami, Chihiro Shiomi, Yoku Hayakawa, Mitsuhiro Fujishiro, Minoru Ono, Issei Komuro
UNLABELLED: Inflammatory bowel disease (IBD) is a complex chronic inflammatory intestinal disease. The development of de novo IBD after solid organ transplantation with immunosuppressive agents has been rarely reported. We present the case of a 65-year-old man with repeated colitis after heart transplantation (HTx) who was diagnosed with Crohn's disease (CD). The patient underwent HTx due to non-ischemic dilated cardiomyopathy. Six months after HTx, he developed serious diarrhea and a transient fever, which persisted for about 6 months...
April 2024: Journal of Cardiology Cases
https://read.qxmd.com/read/38357008/updates-in-the-pathogenesis-and-management-of-immune-related-enterocolitis-hepatitis-and-cardiovascular-toxicities
#2
REVIEW
J McKenzie, E Sneath, A Trinh, M Nolan, L Spain
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant challenge when treating patients with ICI. The underlying pathophysiology of irAE development for many organ systems is yet to be elucidated, but may involve unmasking of latent autoimmunity, increased T-cell recognition of shared antigens on cancer and normal tissue and ICI-triggered immune dysregulation with overactivation of proinflammatory pathways and suppression of immune control pathways...
March 2024: Immunooncol Technol
https://read.qxmd.com/read/38172003/clinical-management-of-gastrointestinal-and-liver-toxicities-of-immune-checkpoint-inhibitors
#3
REVIEW
Kevin Mok, Claudia Wu, Stephen Chan, Grace Wong, Vincent Wai-Sun Wong, Brigette Ma, Rashid Lui
Immune checkpoint inhibitors have transformed the treatment paradigm for various types of cancer. Nonetheless, with the utilization of these groundbreaking treatments, immune-related adverse events (irAEs) are increasingly encountered. Colonic and hepatic involvement are among the most frequently encountered irAEs. Drug-induced side effects, infectious causes, and tumor-related symptoms are the key differentials for irAE complications. Potential risk factors for the development of irAEs include combination use of immune checkpoint inhibitors, past development of irAEs with other immunotherapy treatments, certain concomitant drugs, and a pre-existing personal or family history of autoimmune illness such as inflammatory bowel disease...
December 16, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38148101/ivig-as-a-promising-therapy-for-methotrexate-induced-life-threatening-neutropenic-enterocolitis-in-an-elderly-patient-with-rheumatoid-arthritis-a-case-report-and-literature-review
#4
JOURNAL ARTICLE
Shan-Wen Lui, Jeng-Wei Lu, Yi-Jung Ho, Ting-Yu Hsieh, Fu-Chiang Yeh, Feng-Cheng Liu
BACKGROUND/AIM: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with the functional impairment of multiple joints and the destruction of bone and cartilage. Methotrexate (MTX) is a first-line drug commonly used to treat RA; however, even low doses of MTX can potentially cause rare but severe adverse reactions, such as neutropenic enterocolitis (NE), a life-threatening disease characterized by intestinal mucosal damage and immunodeficiency. CASE REPORT: Here, we report on an 82-year-old RA patient who developed life-threatening NE after ten years of low-dose MTX treatment...
2024: In Vivo
https://read.qxmd.com/read/37752094/development-and-validation-of-a-risk-prediction-model-for-immune-related-adverse-events-in-patients-with-non-small-cell-lung-cancer-receiving-pd-1-pd-l1-inhibitors
#5
JOURNAL ARTICLE
Qing Qiu, Chenghao Wu, Wenxiao Tang, Longfei Ji, Guangwei Dai, Yuzhen Gao, Enguo Chen, Hanliang Jiang, Xinyou Xie, Jun Zhang
Lung cancer remains the leading cause of cancer deaths worldwide and is the most common cancer in males. Immune-checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) have achieved impressive efficacy in the treatment of non-small-cell lung cancer (NSCLC) (Pardoll, 2012; Champiat et al., 2016; Gao et al., 2022). Although ICIs are usually well tolerated, they are often accompanied by immune-related adverse events (irAEs) (Doroshow et al., 2019)...
October 15, 2023: Journal of Zhejiang University. Science. B
https://read.qxmd.com/read/37349130/concurrent-immune-checkpoint-inhibition-and-selective-immunosuppressive-therapy-in-patients-with-immune-related-enterocolitis
#6
MULTICENTER STUDY
Yousef R Badran, Fangwen Zou, Sienna M Durbin, Barbara E Dutra, Hamzah Abu-Sbeih, Anusha S Thomas, Mehmet Altan, John A Thompson, Wei Qiao, Donna E Leet, Po-Ying Lai, Nora K Horick, Michael A Postow, David M Faleck, Yinghong Wang, Michael Dougan
PURPOSE: Immune checkpoint inhibitor (ICI) therapy is often suspended because of immune-related enterocolitis (irEC). We examined the effect of resumption of ICIs with or without concurrent selective immunosuppressive therapy (SIT) on rates of symptom recurrence and survival outcomes. METHODS: This retrospective, multicenter study examined patients who were treated with ICI and developed irEC requiring SIT (infliximab or vedolizumab) for initial symptom control or to facilitate steroid tapering between May 2015 and June 2020...
June 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37038577/the-first-reported-case-of-drug-induced-hemolytic-anemia-by-piperacillin-tazobactam-in-a-premature-neonate-a-case-report-and-literature-review
#7
Hamza Salim, Basel Musmar, Fajr M A Sarhan, Narmeen Giacaman, Shatha Abu Omar
Drugs can have a wide array of effects on hematological cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets. Drug-induced hemolytic anemia (DIHA) can be explained by three different pathophysiological mechanisms. We present a case of a premature neonate born at 34 weeks gestation who was admitted to the neonatal intensive care unit (NICU). He developed respiratory difficulty with mottled skin and was suspected to have bacterial sepsis due to necrotizing enterocolitis (NEC)...
March 2023: Curēus
https://read.qxmd.com/read/36419794/plasma-single-stranded-dna-autoantibodies-in-the-diagnosis-of-hirschsprung-s-disease
#8
JOURNAL ARTICLE
Bingtong Wang, Yongxuan Yao, Wenlin Fang, Yanqing Liu, Wei Zhong, Ye He, Yulu Lai, Qiuming He, Yun Zhu, Chaoting Lan
BACKGROUND: Hirschsprung's disease (HSCR) is a neonatal enteric nervous system (ENS) disease characterized by congenital enteric ganglion cell loss. The only treatment is aganglionic bowel segment resection and innervated bowel segment reconstruction. Delayed diagnosis and treatment cause postoperative complications such as intractable constipation and enterocolitis. Existing preoperative HSCR diagnostic methods have shortcomings such as false positives, radiation and invasiveness. METHODS: We used the robust linear model (RLM) for normalization and the M statistic for screening plasma human autoimmune antigen microarrays and quantitatively assessed single-stranded DNA (ssDNA) antibody levels with enzyme-linked immunosorbent assay (ELISA)...
2022: Frontiers in Medicine
https://read.qxmd.com/read/36286682/-tnfrsf13b-gene-mutation-in-adult-patient-with-common-variable-immunodeficiency-case-report
#9
JOURNAL ARTICLE
P S Sviridov, N A Bodunova, A M Danishevich, M M Litvinova
Common variable immunodeficiency (CVID) is one form of the primary immunodeficiencies (PIDs). CVID is characterized by variable clinical manifestations. Genetic alteration is a cause of the disease in many cases. In the current paper we described Patient N of 45 years old, who have been suffering from frequent various infections and therefore attended an immunologist and clinical geneticist. Immunoglobulins (Ig) A, M, and G deficiency was found in the patient. As a result of medical genetic counselling primary immunodeficiency has been suggested as a diagnosis...
December 15, 2021: Terapevticheskiĭ Arkhiv
https://read.qxmd.com/read/36264425/update-on-immune-checkpoint-inhibitor-enterocolitis
#10
REVIEW
Molly R Kelly-Goss, Yousef R Badran, Michael Dougan
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI) therapy revolutionized the treatment of multiple solid and hematologic malignancies. Yet, with it came profound inflammatory toxicities that mimic autoimmune diseases, termed immune-related adverse events (irAEs). Prominent among these is gastrointestinal inflammation, including a spectrum of gastritis, enteritis, and colitis. Here we synthesize an approach to immune checkpoint related enterocolitis (irEC) - including diagnostics and therapeutics - underpinned by new insights into the mechanism behind these phenomena...
December 2022: Current Gastroenterology Reports
https://read.qxmd.com/read/35986143/sars-cov-2-detected-in-neonatal-stool-remote-from-maternal-covid-19-during-pregnancy
#11
JOURNAL ARTICLE
Jenny C Jin, Aparna Ananthanarayanan, Julia A Brown, Stephanie L Rager, Yaron Bram, Katherine Z Sanidad, Mohammed Amir, Rebecca N Baergen, Heidi Stuhlmann, Robert E Schwartz, Jeffrey M Perlman, Melody Y Zeng
BACKGROUND: In utero transmission of SARS coronavirus 2 (SARS-CoV-2) has not been fully investigated. We investigated whether newborns of mothers with COVID-19 during pregnancy might harbor SARS-CoV-2 in the gastrointestinal tract. METHODS: This cohort study investigated stool from 14 newborns born at 25-41 weeks admitted at delivery to our urban academic hospital whose mothers had COVID-19 during pregnancy. Eleven mothers had COVID-19 resolved more than 10 weeks before delivery...
August 19, 2022: Pediatric Research
https://read.qxmd.com/read/35950386/-clinical-features-of-immune-checkpoint-inhibitor-related-myositis-in-patients-with-urological-cancer
#12
JOURNAL ARTICLE
Y C Ying, Q Tang, K W Yang, Y Mi, Y Fan, W Yu, Y Song, Z S He, L Q Zhou, X S Li
OBJECTIVE: Immune checkpoint inhibitors (ICI) have significantly improved the treatment efficacy of a variety of malignant tumors. However, patients may experience a series of special side effects during treatments with ICI. Immune-related myositis after ICI treatment is characterized by autoimmune rheumatic and musculoskeletal damage, which is relatively rare. To analyze the clinical characteristics and outcomes of ICI-associated myositis in urological tumors, we summarized the clinical manifestations, electrophysiological and pathological characteristics, treatments and outcomes in 8 patients...
August 18, 2022: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://read.qxmd.com/read/35537412/interleukin-6-blockade-abrogates-immunotherapy-toxicity-and-promotes-tumor-immunity
#13
JOURNAL ARTICLE
Yared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata, Sang T Kim, Roza Nurieva, Alexander J Lazar, Hamzah Abu-Sbeih, Faisal Fa'ak, Antony Mathew, Yinghong Wang, Adewunmi Falohun, Van Trinh, Chrystia Zobniw, Christine Spillson, Jared K Burks, Muhammad Awiwi, Khaled Elsayes, Luisa Solis Soto, Brenda D Melendez, Michael A Davies, Jennifer Wargo, Jonathan Curry, Cassian Yee, Gregory Lizee, Shalini Singh, Padmanee Sharma, James P Allison, Patrick Hwu, Suhendan Ekmekcioglu, Adi Diab
Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of interleukin-6 (IL-6), neutrophil, and chemotactic markers was higher in colitis than in normal intestinal tissue; T helper 17 (Th17) cells were more prevalent in immune-related enterocolitis (irEC) than T helper 1 (Th1)...
May 9, 2022: Cancer Cell
https://read.qxmd.com/read/35502510/severe-graft-versus-host-disease-like-enterocolitis-accompanied-with-cytomegalovirus-reactivation-in-drug-induced-hypersensitivity-syndrome-drug-reaction-with-eosinophilia-and-systemic-symptoms
#14
JOURNAL ARTICLE
Saeko Takamiyagi, Hisato Iriki, Yasuhiko Asahina, Yuki Furuichi, Takeru Funakoshi, Masataka Ichikawa, Yohei Mikami, Hajime Okita, Tomo Sakiyama, Toyoko Inazumi, Masayuki Amagai, Hayato Takahashi
Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug adverse reaction with skin eruption and visceral organ involvement. The characteristic clinical features of DIHS/DRESS are reactivation of human herpesviruses (HHV) and the development of autoimmune diseases, but their pathogenesis and associations are not yet understood. Here, we report a 66-year-old man who presented with fever, generalized erythema, diffuse lymphadenopathy, and diarrhea after 3 weeks of treatment with zonisamide...
August 2022: Journal of Dermatology
https://read.qxmd.com/read/34949979/the-evolution-of-very-early-onset-inflammatory-bowel-disease-autoimmune-hepatitis-and-primary-sclerosing-cholangitis-in-a-young-girl
#15
Aditi Dey, Jacquelin Peck, Michael Wilsey, Jolan Walter, Johnny Nguyen, Ignacio Gonzalez-Gomez, Sara Karjoo
Very early onset inflammatory bowel disease, autoimmune hepatitis (AIH), or primary sclerosing cholangitis (PSC) alone is a rare condition in young children. The combination of all 3 autoimmune disorders in a 16-month-old child is even rarer. The onset and etiology of these diseases is multifactorial and typically unknown. However, when the children are diagnosed, the accepted view point is that the inflammation was likely present for months to years prior. This case is unique because the gastrointestinal problems started from infancy, and evolved to the development of Crohn's disease, AIH, and PSC at a very early age...
September 2021: Case Reports in Gastroenterology
https://read.qxmd.com/read/34572236/human-milk-oligosaccharides-a-comprehensive-review-towards-metabolomics
#16
REVIEW
Laura Corona, Anna Lussu, Alice Bosco, Roberta Pintus, Flaminia Cesare Marincola, Vassilios Fanos, Angelica Dessì
Human milk oligosaccharides (HMOs) are the third most represented component in breast milk. They serve not only as prebiotics but they exert a protective role against some significant neonatal pathologies such as necrotizing enterocolitis. Furthermore, they can program the immune system and consequently reduce allergies and autoimmune diseases' incidence. HMOs also play a crucial role in brain development and in the gut barrier's maturation. Moreover, the maternal genetic factors influencing different HMO patterns and their modulation by the interaction and the competition between active enzymes have been widely investigated in the literature, but there are few studies concerning the role of other factors such as maternal health, nutrition, and environmental influence...
September 14, 2021: Children
https://read.qxmd.com/read/34434439/immunoglobulin-g4-related-disease-a-rare-presentation-with-secondary-hypereosinophilic-syndrome-and-eosinophilic-ascites
#17
Luisa Serpa Pinto, Nuno Jorge Lamas, Ana Campar, Alvaro Ferreira, Ana Rita Cruz
Immunoglobulin G4 related-disease (IgG4-RD) is a multisystemic immune-mediated fibroinflammatory disease, with a strong predilection for salivary and lacrimal glands, pancreas, biliary tree, lungs, kidneys, aorta, and retroperitoneum. In the case of pancreatic involvement, it manifests as autoimmune pancreatitis. Patients with IgG4-RD usually have mild to moderate eosinophilia in the peripheral blood, however, they may present a secondary hypereosinophilic syndrome (HES). Although there are cases described with severe eosinophilia (> 5,000/µL), the 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-RD considers peripheral eosinophilia above 3,000/µL as an exclusion criterion, although stating that assessment for the presence of exclusion criteria should be individualized depending on a patient's clinical scenario...
March 2021: Journal of Medical Cases
https://read.qxmd.com/read/34430206/passage-of-intestinal-casts-an-unusual-presentation-of-cytomegalovirus-enterocolitis
#18
Nisakorn Limthanetkul, Dussadee Sakonlaya, Sith Siramolpiwat
Cytomegalovirus (CMV) is one of the leading opportunistic pathogens affecting immunocompromised patients. We report a case of histologically-confirmed extensive CMV enterocolitis in a young woman after receiving rituximab and tocilizumab for the treatment of autoimmune encephalitis. During the antiviral treatment, she spontaneously excreted small intestinal casts per oral and colonic casts per anus. Even though intestinal cast is an extremely unusual condition, CMV infection should be included in the differential diagnosis...
2021: IDCases
https://read.qxmd.com/read/34233964/clinical-outcomes-of-patients-with-corticosteroid-refractory-immune-checkpoint-inhibitor-induced-enterocolitis-treated-with-infliximab
#19
MULTICENTER STUDY
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen McHugh, David J Pinato, Paul Nathan, Julia Choy, Shanthini M Crusz, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Julian P Teare, Sophie Papa, Ally Speight, Anand Sharma, Nick Powell
INTRODUCTION: Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refractory cases. However, robust outcome data for these patients are scarce. METHODS: We conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020...
July 2021: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/33827474/parallel-disease-activity-of-beh%C3%A3-et-s-disease-with-renal-and-entero-involvements-a-case-report
#20
JOURNAL ARTICLE
Kanako Watanabe-Kusunoki, Masaru Kato, Yotaro Oki, Tetsuo Shimizu, Yoshihiro Kusunoki, Shota Furukawa, Shin Furukawa, Hirohiko Kitakawa, Kiyoshi Sakai
BACKGROUND: Behçet's disease (BD) is a systemic inflammatory vasculitis with both autoimmune and autoinflammatory properties. Renal involvement in BD and its spontaneous remission have been rare. We herein describe a case of parallel disease activity of BD with entero and renal involvements, followed by a spontaneous remission without corticosteroid treatment. CASE PRESENTATION: A 54-year-old woman who had a 4-year history of BD, maintained with colchicine treatment, suffered abdominal pain, hemorrhagic stool and diarrhea...
April 7, 2021: BMC Nephrology
keyword
keyword
114977
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.